The Peptide Field
Menu

Sources · 208 listed

Sources behind the answers.

Find the sources behind these pages: drug labels, agency records, studies in people, and early studies in cells or animals. Each source shows which peptide reviews use it.

Narrow the list

Filters

Showing 1–20 of 208 sources

Source types explained

Official records and labels include agency records and product labels. Studies in people test a substance in people. Trial plans and status show planned or ongoing studies; they may not include results. Body changes in people covers studies of how a substance acts in people. Reviews and early studies cover research reviews and studies in cells or animals.

01
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-08-30

OZEMPIC (semaglutide) prescribing information, revised 05/2026

Reviews using this sourceSemaglutide
Open source
02
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-08-30

RYBELSUS (semaglutide) prescribing information, revised 10/2025

Reviews using this sourceSemaglutide
Open source
03
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-08-30

WEGOVY (semaglutide) prescribing information, revised 06/2026

Reviews using this sourceSemaglutide
Open source
06
PreclinicalPubMed · Journal of Medicinal Chemistry · 2015Checked 2026-08-30

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

Reviews using this sourceSemaglutide
Open source
07
ReferenceU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA substance record: semaglutide identity (not an approval record)

Reviews using this sourceSemaglutide
Open source
08
Anti-dopingWorld Anti-Doping Agency · 2026Checked 2026-08-30

2026 Monitoring Program

Reviews using this sourceSemaglutide
Open source
09
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

Insulin: patient and product overview

Reviews using this sourceInsulin
Open source
10
Drug labelDailyMed · National Library of Medicine · 2026Checked 2026-08-30

HUMALOG (insulin lispro) label, updated June 2026

Reviews using this sourceInsulin
Open source
11
Drug labelU.S. Food and Drug Administration · 2025Checked 2026-08-30

HUMALOG (insulin lispro) FDA prescribing information, revised 05/2025

Reviews using this sourceInsulin
Open source
12
Randomized trialPubMed · New England Journal of Medicine · 1993Checked 2026-08-30

The effect of intensive treatment of diabetes on long-term complications in insulin-dependent diabetes mellitus

Reviews using this sourceInsulin
Open source
13
Randomized trialPubMed · Diabetes · 1997Checked 2026-08-30

Hypoglycemia in the Diabetes Control and Complications Trial

Reviews using this sourceInsulin
Open source
14
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA approves the first rapid-acting insulin biosimilar product for diabetes

Reviews using this sourceInsulin
Open source
15
RegulatoryU.S. Food and Drug Administration · 2026Checked 2026-08-30

Biosimilars basics for patients

Reviews using this sourceInsulin
Open source
17
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-10-12

MOUNJARO (tirzepatide) prescribing information, revised August 2026

Reviews using this sourceTirzepatide
Open source
18
Drug labelU.S. Food and Drug Administration · 2026Checked 2026-08-30

ZEPBOUND (tirzepatide) prescribing information, revised February 2026

Reviews using this sourceTirzepatide
Open source
19
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA approval letter: Mounjaro heart-risk indication, August 27, 2026

Reviews using this sourceTirzepatide
Open source
20
FDA reviewU.S. Food and Drug Administration · 2026Checked 2026-08-30

FDA supplement letter: Zepbound cardiovascular-trial information, August 26, 2026

Reviews using this sourceTirzepatide
Open source

About this list

How this list works

This list includes sources used in the peptide reviews. Each source appears once, followed by the reviews that use it. Guide citations stay on their guide pages. A source here may support some claims, not every claim, about a peptide.